Federal Contractor Profile
Abviro LLC
Federal contracting record: $41M obligated across 2 awards from 1 agencies, FY 2016–2026.
$41M
Total Obligated
2
Award Records
1
Agencies Served
2
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
K3L6KXJ9B6M7
CAGE Code
75YF3
Address
4800 HAMPDEN LN STE 200, BETHESDA, MD, 208142934
First Federal Award
Sep 19, 2016
Most Recent Award
Mar 24, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$41M
100.0% of total obligations
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Mar 24, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. | $2.6M |
| Jul 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. | $6.2M |
| Feb 14, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. | $755K |
| Sep 21, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. | $1.8M |
| Jan 23, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $9K |
| Dec 9, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $2.6M |
| Jun 26, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $3.2M |
| Sep 12, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $2.1M |
| Apr 4, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $3.3M |
| Feb 5, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $3.9M |
| Aug 22, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $9.4M |
| Sep 19, 2016 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $5.2M |
Want to win work like Abviro LLC?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.